Ionis Pharmaceuticals (NASDAQ:IONS) Chairman Stanley T. Crooke sold 13,962 shares of the stock in a transaction that occurred on Tuesday, April 17th. The shares were sold at an average price of $44.40, for a total value of $619,912.80. Following the completion of the sale, the chairman now directly owns 56,714 shares of the company’s stock, valued at approximately $2,518,101.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Ionis Pharmaceuticals stock opened at $48.51 on Friday. The company has a market capitalization of $5,774.09, a P/E ratio of 606.38 and a beta of 2.49. Ionis Pharmaceuticals has a fifty-two week low of $40.33 and a fifty-two week high of $65.51. The company has a quick ratio of 5.15, a current ratio of 5.20 and a debt-to-equity ratio of 1.45.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.10. The company had revenue of $172.00 million during the quarter, compared to analyst estimates of $126.38 million. Ionis Pharmaceuticals had a negative return on equity of 1.94% and a negative net margin of 1.18%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 earnings per share. equities research analysts predict that Ionis Pharmaceuticals will post -0.13 EPS for the current year.
IONS has been the subject of several recent research reports. Zacks Investment Research cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 10th. BidaskClub cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 22nd. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $55.00 price target (down previously from $61.00) on shares of Ionis Pharmaceuticals in a report on Tuesday, February 20th. TheStreet cut Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus increased their price target on Ionis Pharmaceuticals from $55.00 to $57.00 and gave the company a “hold” rating in a report on Wednesday, February 28th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $52.15.
A number of institutional investors have recently modified their holdings of IONS. The Manufacturers Life Insurance Company grew its position in Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after acquiring an additional 311 shares during the period. Great West Life Assurance Co. Can grew its position in Ionis Pharmaceuticals by 9.0% in the third quarter. Great West Life Assurance Co. Can now owns 13,296 shares of the company’s stock worth $698,000 after acquiring an additional 1,096 shares during the period. Legal & General Group Plc grew its position in Ionis Pharmaceuticals by 18.8% in the third quarter. Legal & General Group Plc now owns 52,837 shares of the company’s stock worth $2,679,000 after acquiring an additional 8,357 shares during the period. JPMorgan Chase & Co. grew its position in Ionis Pharmaceuticals by 444.0% in the third quarter. JPMorgan Chase & Co. now owns 62,572 shares of the company’s stock worth $3,292,000 after acquiring an additional 80,763 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Ionis Pharmaceuticals by 3.7% in the third quarter. Dimensional Fund Advisors LP now owns 204,022 shares of the company’s stock worth $10,347,000 after acquiring an additional 7,210 shares during the period. Institutional investors own 90.91% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/21/stanley-t-crooke-sells-13962-shares-of-ionis-pharmaceuticals-ions-stock.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.